For patients across all indications treated within the RP2D range early, promising progression-free survival (PFS) and ...

Novel combination with neoadjuvant eftilagimod alfa (efti) achieves significant 51.5% tumour hyalinization/fibrosis across multiple soft tissue ...

BioAtla (NASDAQ:BCAB) achieved FDA alignment on phase three trial design, dosing, comparator, and endpoints for the OSV ...

Q3 2025 Earnings Call Transcript November 13, 2025 Operator: You all sites on hold. We appreciate your patience, and please ...

The Australian market is experiencing turbulence, with the ASX 200 futures indicating a significant drop following the recent end of the U.S. government shutdown and ongoing economic uncertainties.

Q3 2025 Earnings Call November 13, 2025 4:30 PM ESTCompany ParticipantsJay Short - Co-Founder, CEO & ChairmanSheri Lydick - ...

Day One Biopharmaceuticals, Inc. is rated a Strong Buy with robust product growth, pipeline expansion & strategic acquisition ...

Researchers have designed a smart drug that hunts down and breaks a little-known RNA that cancer cells depend on. The drug ...

HER back pain was so debilitating she couldn’t sleep and had to crawl to the bathroom. Even more frighteningly, she was ...

A study harnessing a successful treatment for lymphoma and applying it to other cancers promises a breakthrough in how to attack a range of tumours using the body’s own immune system.

First-in-class dendritic cell (DC) maturation agent Plinabulin drives immune re-sensitization in metastatic NSCLC ...

A 55-year-old man presented to the ED for a chronic right upper extremity wound. The lesion began as a small bump 3 years ...